Literature DB >> 17993768

sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.

K K Doumouchtsis1, A I Kostakis, S K Doumouchtsis, M P Tziamalis, C Tsigris, M A Kostaki, D N Perrea.   

Abstract

OBJECTIVE: The processes involved in bone remodeling are under the control of a multitude of systemic and local factors. Receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) complex seems to be one of the major modulators of bone remodeling. In chronic renal failure, the cytokine systems involved in the regulation of bone turnover may be influenced, and are therefore likely to contribute to the pathogenesis of renal bone disease. The aim of the present study was the evaluation of RANKL/OPG complex in concert with other biochemical parameters in hemodialysis (HD) patients and the investigation of possible correlations between the serum levels of its components and several clinical parameters of these patients.
METHODS: We measured serum levels of intact PTH (iPTH), total serum RANKL (sRANKL), osteoprotegerin (OPG), alkaline phosphatase, osteocalcin (OC), and tartrate-resistant acid phosphatase (TRAP) in 104 HD patients and in 40 healthy controls.
RESULTS: The average serum OPG level was significantly higher, whereas the average serum concentration of RANKL was nonsignificantly lower in patients on HD therapy than in age-matched healthy controls. Consequently, the mean sRANKL/OPG ratio was significantly lower in patients. Among HD patients, serum level of OPG increased significantly with aging and with a longer duration of hemodialysis. RANKL levels were inversely correlated with age nonsignificantly in the whole group of patients and significantly in the female subgroup (r=-0.322, p=0.035), whereas RANKL/OPG ratio declined significantly with age in the entire cohort of patients (r=-0.259, p=0.008). In addition, iPTH, OC, TRAP were significantly higher in female, whereas RANKL/OPG ratio was significantly higher in male than female patients.
CONCLUSIONS: Lower values of sRANKL/OPG ratio in HD patients, as well as the age and duration of HD dependent increase of serum OPG and the age-dependent decrease of sRANKL concentration especially in women cannot be explained by the elimination of renal clearance only. Alterations in sRANKL/OPG ratio might reflect a compensatory mechanism to modulate bone remodeling in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17993768     DOI: 10.1007/BF03350814

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  22 in total

Review 1.  Minireview: the OPG/RANKL/RANK system.

Authors:  S Khosla
Journal:  Endocrinology       Date:  2001-12       Impact factor: 4.736

2.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

3.  Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures.

Authors:  K Matsuzaki; N Udagawa; N Takahashi; K Yamaguchi; H Yasuda; N Shima; T Morinaga; Y Toyama; Y Yabe; K Higashio; T Suda
Journal:  Biochem Biophys Res Commun       Date:  1998-05-08       Impact factor: 3.575

4.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts.

Authors:  Yuko Nakamichi; Nobuyuki Udagawa; Yasuhiro Kobayashi; Midrori Nakamura; Yohei Yamamoto; Teruhito Yamashita; Toshihide Mizoguchi; Masahiro Sato; Makio Mogi; Josef M Penninger; Naoyuki Takahashi
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

6.  Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.

Authors:  Astrid Fahrleitner-Pammer; Harald Dobnig; Claudia Piswanger-Soelkner; Christine Bonelli; Hans-Peter Dimai; Georg Leb; Barbara Obermayer-Pietsch
Journal:  Wien Klin Wochenschr       Date:  2003-05-15       Impact factor: 1.704

7.  Increased serum osteoprotegerin level in older and diabetic hemodialysis patients.

Authors:  Shigehiro Doi; Noriaki Yorioka; Takao Masaki; Takafumi Ito; Kenichiro Shigemoto; Satoru Harada
Journal:  Ther Apher Dial       Date:  2004-08       Impact factor: 1.762

8.  Correlates of osteoprotegerin levels in women and men.

Authors:  S Khosla; H M Arrighi; L J Melton; E J Atkinson; W M O'Fallon; C Dunstan; B L Riggs
Journal:  Osteoporos Int       Date:  2002-05       Impact factor: 4.507

9.  Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.

Authors:  T Akatsu; T Murakami; M Nishikawa; K Ono; N Shinomiya; E Tsuda; S Mochizuki; K Yamaguchi; M Kinosaki; K Higashio; M Yamamoto; K Motoyoshi; N Nagata
Journal:  Biochem Biophys Res Commun       Date:  1998-09-18       Impact factor: 3.575

10.  The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Authors:  T L Burgess; Y Qian; S Kaufman; B D Ring; G Van; C Capparelli; M Kelley; H Hsu; W J Boyle; C R Dunstan; S Hu; D L Lacey
Journal:  J Cell Biol       Date:  1999-05-03       Impact factor: 10.539

View more
  10 in total

1.  An osteoclastogenesis system, the RANKL/RANK signalling pathway, contributes to aggravated allergic inflammation.

Authors:  Sun-Young Nam; Hee-Yun Kim; Jin-Young Min; Hyung-Min Kim; Hyun-Ja Jeong
Journal:  Br J Pharmacol       Date:  2019-04-15       Impact factor: 8.739

Review 2.  Muscle-Bone Crosstalk in Chronic Kidney Disease: The Potential Modulatory Effects of Exercise.

Authors:  Diogo V Leal; Aníbal Ferreira; Emma L Watson; Kenneth R Wilund; João L Viana
Journal:  Calcif Tissue Int       Date:  2021-01-02       Impact factor: 4.333

3.  Serum osteoprotegerin is markedly increased and may contribute to decreased blood T cell count in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Efi Yiannaki; Vassilios Liakopoulos; Georgia Antoniadi; Georgios Pissas; Grammati Galaktidou; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2013-01-08       Impact factor: 2.370

4.  Comparative study of quantitative ultrasonography and dual-energy X-ray absorptiometry for evaluating renal osteodystrophy in children with chronic kidney disease.

Authors:  Athanasios Christoforidis; Nikoleta Printza; Chrysa Gkogka; Ekaterini Siomou; Anna Challa; Eirini Kazantzidou; Konstantinos Kollios; Fotis Papachristou
Journal:  J Bone Miner Metab       Date:  2010-09-16       Impact factor: 2.626

5.  Biochemical markers of vascular calcification in elderly hemodialysis patients.

Authors:  Alvaro Osorio; Esperanza Ortega; Jesús M Torres; Pilar Sanchez; Estrella Ruiz-Requena
Journal:  Mol Cell Biochem       Date:  2012-11-03       Impact factor: 3.396

Review 6.  Non-crystalline and crystalline rheumatic disorders in chronic kidney disease.

Authors:  Pasha Sarraf; Jonathan Kay; Anthony M Reginato
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

7.  Determination of NF-κB and RANKL levels in peripheral blood osteoclast precursor cells in chronic kidney disease patients.

Authors:  Gülcan Güneş; Nil Doğruer Ünal; Gülçin Eskandari; Ahmet Kiykim; Özlem Bölgen Çimen; Gülhan Temel; Mehmet Burak Y Çimen
Journal:  Int Urol Nephrol       Date:  2018-04-11       Impact factor: 2.370

8.  Impact of the uremic milieu on the osteogenic potential of mesenchymal stem cells.

Authors:  Diana Lanza; Alessandra F Perna; Adriana Oliva; Raymond Vanholder; Anneleen Pletinck; Salvatore Guastafierro; Annarita Di Nunzio; Carmela Vigorito; Giovambattista Capasso; Vera Jankowski; Joachim Jankowski; Diego Ingrosso
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

9.  Pit- and trench-forming osteoclasts: a distinction that matters.

Authors:  Ditte Mh Merrild; Dinisha C Pirapaharan; Christina M Andreasen; Per Kjærsgaard-Andersen; Anaïs Mj Møller; Ming Ding; Jean-Marie Delaissé; Kent Søe
Journal:  Bone Res       Date:  2015-12-01       Impact factor: 13.567

10.  Comprehensive assessment of tissue and serum parameters of bone metabolism in a series of orthopaedic patients.

Authors:  Jan Gunsser; Regina Hermann; Andreas Roth; Amelie Lupp
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.